0000000000241175

AUTHOR

Juan V Mulet Bayona

showing 5 related works from this author

Impact of the SARS-CoV-2 Pandemic in Candidaemia, Invasive Aspergillosis and Antifungal Consumption in a Tertiary Hospital

2021

In addition to the increase in fungal infections that has been observed in the last few decades, it has been reported that severe clinical COVID-19 can increase the risk of invasive fungal infections. The main objective of this study was to evaluate if there had been an increase in candidaemia and invasive pulmonary aspergillosis (IPA) cases since the onset of the SARS-CoV-2 pandemic. Data were retrospectively collected from April 2019 to March 2021, from patients admitted to Consorcio Hospital General Universitario de Valencia (Spain). A total of 152 candidaemia cases (56 of which were due to Candida auris) and 108 possible IPA cases were detected. A great increase in candidaemia cases was…

Microbiology (medical)Antifungalmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.drug_classQH301-705.5Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IFIPlant ScienceAspergillosisArticle03 medical and health sciences0302 clinical medicineInternal medicinePandemicmedicinecandidaemiaaspergillosis030212 general & internal medicineBiology (General)skin and connective tissue diseasesEcology Evolution Behavior and SystematicsVoriconazole0303 health sciences030306 microbiologybusiness.industryMortality rateisavuconazoleCOVID-19medicine.diseaserespiratory tract diseasesCandida aurisbusinessantifungalsmedicine.drugJournal of Fungi
researchProduct

Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar™ Candida for the detection of Candida auris in…

2020

Abstract A shift to Candida non-albicans infections has been noted during the last years, and the emergence of multi-resistant Candida auris has complicated their management. The aim of this study was first to compare the performance of the novel chromogenic medium CHROMagar™ Candida Plus (CHROMagar, France) with CHROMagar™ Candida (Becton Dickinson, Germany) for the presumptive identification of Candida species; and then, to evaluate its utility in the detection of C. auris in surveillance samples. CHROMagar™ Candida Plus showed a good performance compared with the reference medium CHROMagar™ Candida. Sensitivity and specificity were 100% in both media for tested species at 48 h of incubat…

0301 basic medicineMicrobiology (medical)030106 microbiologySensitivity and SpecificityMicrobiology03 medical and health sciencesfluids and secretions0302 clinical medicineHumans030212 general & internal medicineMycological Typing TechniquesCandidaCandida glabratabiologyChromogenicCandida lusitaniaeBecton dickinsonCandidiasisGeneral Medicinebacterial infections and mycosesequipment and suppliesbiology.organism_classificationCulture MediaInfectious DiseasesCandida aurisChromogenic CompoundsCandida sppChromagar candidaDiagnostic microbiology and infectious disease
researchProduct

Characteristics and Management of Candidaemia Episodes in an Established Candida auris Outbreak

2020

The multi-resistant yeast Candida auris has become a global public health threat because of its ease to persist and spread in clinical environments, especially in intensive care units. One of the most severe manifestations of invasive candidiasis is candidaemia, whose epidemiology has evolved to more resistant non-albicansCandida species, such as C. auris. It is crucial to establish infection control policies in order to control an outbreak due to nosocomial pathogens, including the implementation of screening colonisation studies. We describe here our experience in managing a C. auris outbreak lasting more than two and a half years which, despite our efforts in establishing control measure…

0301 basic medicineMicrobiology (medical)medicine.medical_specialty<i>Candida auris</i>colonisation030106 microbiologymultidrug-resistantyeastBiochemistryMicrobiology03 medical and health sciences0302 clinical medicineInternal medicineIntensive careAmphotericin BEpidemiologyInfection controlMedicinecandidaemiaPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsoutbreakbusiness.industryMortality ratelcsh:RM1-950Outbreaklcsh:Therapeutics. PharmacologyInfectious DiseasesCandida aurissurveillancefungibusinessFluconazolemedicine.drugAntibiotics
researchProduct

Validation and implementation of a commercial real-time PCR assay for direct detection of Candida auris from surveillance samples.

2021

Background Rapid and reliable laboratory methods are required for detecting the nosocomial yeast Candida auris. AurisID® (Olm Diagnostics, England) is a real-time PCR assay approved for detecting C. auris in fungal cultures as well as directly from blood samples, involving a nucleic acid extraction as a prior step. Objectives The purpose of this study is to validate the AurisID® kit for direct detection of C. auris from surveillance samples without prior DNA extraction and to analyze the results of implementing this methodology to our daily laboratory routine protocol for C. auris surveillance studies. Methods Our PCR method using the AurisID® kit was compared with our routine protocol, con…

0301 basic medicineSerial dilution030106 microbiologyPcr assayDermatologyReal-Time Polymerase Chain ReactionSensitivity and Specificity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineLimit of DetectionTransport mediumMedicineHumansDNA FungalCandidaDetection limitCross InfectionChromatographybusiness.industryDiagnostic Tests RoutineCandidiasisGeneral MedicineDNA extractionInfectious DiseasesReal-time polymerase chain reactionCandida aurisMolecular Diagnostic TechniquesEpidemiological MonitoringPcr methodbusinessMycosesREFERENCES
researchProduct

Candida auris: descripción de un brote

2020

Resumen Candida auris es una levadura multirresistente emergente que causa infecciones invasivas graves y brotes con una alta mortalidad. El control de C . auris es un reto. Laboratorios, clinicos e instituciones sanitarias deben trabajar conjuntamente para mejorar la identificacion y el tratamiento de la infeccion, asi como el control de la transmision. Esta revision describe los aspectos generales de la biologia, diagnostico y tratamiento de C. auris, al igual que las recomendaciones publicadas recientemente por un grupo de expertos. Tambien se presenta la experiencia de un brote de C. auris en el Consorcio Hospital General Universitario de Valencia desde septiembre de 2017 hasta agosto d…

0301 basic medicineMicrobiology (medical)03 medical and health sciences0302 clinical medicine030106 microbiology030212 general & internal medicineEnfermedades Infecciosas y Microbiología Clínica
researchProduct